SCHEMBL20744375

SCHEMBL20744375

CCOc1cc(-c2cc(F)cc(C(C)C)c2N)ccn1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 5/20 0.41
HRH4 Q9H3N8 2/20 0.35
AAK1 Q2M2I8 4/20 0.33
ACACB O00763 3/20 0.32
ALOX5AP P20292 1/20 0.32
FEN1 P39748 1/20 0.32
NPC1 O15118 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPK1 P28482 1/20 0.32
RAB9A P51151 1/20 0.32
PDE10A Q9Y233 1/20 0.32
ACVR2A P27037 1/20 0.32
TGFBR2 P37173 1/20 0.32
MAPK13 O15264 1/20 0.31
MAPK12 P53778 1/20 0.31
MAPK11 Q15759 1/20 0.31
MAPK14 Q16539 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30684077 1.00 NLRP3 (0.41) NLRP3HRH4AAK1ACACBALOX5AP
SCHEMBL29927552 0.88 NLRP3 (0.48) NLRP3AAK1ACVR2ATGFBR2MAPK13
SCHEMBL20609796 0.88 NLRP3 (0.48) NLRP3AAK1ACVR2ATGFBR2MAPK13
SCHEMBL20742969 0.87 MAPK14 (0.42) NLRP3HRH4ACACBALOX5APFEN1
SCHEMBL30684129 0.87 MAPK14 (0.42) NLRP3HRH4ACACBALOX5APFEN1
SCHEMBL20744369 0.83 MAP4K4 (0.41) NLRP3HRH4AAK1ALOX5APFEN1
SCHEMBL30684145 0.83 MAP4K4 (0.41) NLRP3HRH4AAK1ALOX5APFEN1
SCHEMBL23012692 0.82 ADORA2B (0.43) NLRP3HRH4AAK1ALOX5APFEN1
SCHEMBL20744447 0.82 DYRK1A (0.39) NLRP3HRH4AAK1ALOX5APFEN1
SCHEMBL29573583 0.82 ADORA2B (0.43) NLRP3HRH4AAK1ALOX5APFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111132974-B Sulfonamide carboxamide compounds 英夫拉索姆有限公司 2023-11-21 CN disclosed
US-20200361895-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2020-11-19 US disclosed
US-20200361895-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2020-11-19 US disclosed
EP-3668861-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS Inflazome Limited (IE) 2020-06-24 EP disclosed
CN-111132974-A Novel sulfonamide carboxamide compounds 英夫拉索姆有限公司 2020-05-08 CN disclosed
WO-2019034686-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2019-02-21 WO disclosed
WO-2019034686-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2019-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200361895-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS NLRP3, NOD1, NLRP1 NLRP3 1/4885HRH4 1108/4885AAK1 3504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.